Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 01/15 11:30:00 am
1576.5 GBX   -0.69%
01/12European ADRs Move Higher in Tuesday Trading
MT
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
AQ
01/11European ADRs Move Sharply Lower in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Smith+Nephew CEO steps down over pay, ex-Roche Diagnostics chief to take over

10/21/2019 | 08:17am EST
FILE PHOTO: Roland Diggelmann attends a news conference in Basel, Switzerland, February 1, 2017, as Roche Diagnostics CEO.

(Reuters) - Smith+Nephew Plc Chief Executive Namal Nawana is stepping down after just 17 months in the role after becoming dissatisfied with his salary at the medical device maker.

The company said Nawana, who will be replaced by former Roche Diagnostics head Roland Diggelmann, was leaving to pursue opportunities outside the United Kingdom and his departure was a mutual decision. A spokeswoman gave no additional details.

"There appears to be a pretty simple reason Nawana is leaving – pay," AJ Bell investment director Russ Mould said.

"It became apparent over the summer that the company was looking for ways to increase its head honcho's remuneration with apparent discussions about a move to a U.S. listing to escape an increasing backlash in the UK towards excessive executive pay."

An earlier FT report had said Smith+Nephew directors discussed moving the company's main listing from London to New York, where higher executive payouts are more common and less controversial, to boost its top salaries.

Analysts at Berenberg also said Nawana's pay "aspirations" made his departure inevitable. Nawana, who steps down at the end of the month, did not respond to request for comment on LinkedIn.

Faced with stricter rules in the United Kingdom designed to tackle soaring executive pay, the company is in talks with shareholders over its 2020 remuneration policy.

Nawana, who joined the British maker of artificial knees and hips in May 2018, received total pay of $2.88 million that year, according to the company's last annual report. His predecessor Olivier Bohuon received $5.12 million in 2017.

Smith+Nephew shares, which have risen 40% since Nawana's appointment last year, fell 8.2% on Monday.

PRODUCT DIVISIONS

Nawana had focused on boosting revenue and profitability by realigning the 160-year-old company's operations, concentrating on product divisions rather than geographies.

He was former head of U.S. diagnostics company Alere - where he earned $8.6 mln in 2016 - and overhauled more than half of Smith+Nephew's leadership team. He hired heads for the company's main divisions of sports medicine, orthopaedics and wound management to speed up product development.

Results came quickly as the company reported higher than expected half-year profit and boosted its 2019 revenue forecast in July.

Analysts expect Smith+Nephew's revenue to rise more than 4% this fiscal year, compared with the 0.8% to 3% growth the company has had over the last three years.

Smith+Nephew is looking to Diggelmann, with more than 20 years in the orthopedics and diagnostics sectors, to continue revenue growth by building on Nawana's strategy. He has already had a hand in many decisions having been a board member since March last year.

"We expect (Diggelmann) to pursue a strategy of improving operational execution, something any competitor of Roche Diagnostics would say he did extremely well," Berenberg analyst Tom Jones said.

High executive pay has become a controversial issue in Britain, highlighted by outsized awards such as a $100 million pounds bonus to Jeff Fairburn, chief executive of housebuilder Persimmon. The company said in November he would leave after deciding criticism of the award had become a distraction.

Regulations introduced in January mean listed companies with over 250 employees will have to disclose the ratio of CEO pay to the rest of the company's workforce, in a move the government said would make companies justify the pay of top bosses.

(Reporting by Uday Sampath and Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich and David Holmes)

By Uday Sampath Kumar


© Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
NEXT PLC 0.73% 8018 Delayed Quote.12.39%
PERSIMMON PLC 0.67% 2690 Delayed Quote.-3.51%
SMITH & NEPHEW PLC -0.66% 1577 Delayed Quote.5.26%
TEAM, INC. -7.86% 10.9 Delayed Quote.8.53%
All news about SMITH & NEPHEW PLC
01/12European ADRs Move Higher in Tuesday Trading
MT
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
AQ
01/11European ADRs Move Sharply Lower in Monday Trading
MT
01/11SMITH & NEPHEW : Warns of Revenue, Margin Hit for 2020
DJ
01/11SMITH & NEPHEW : Expects Q4, FY20 Revenue Drop On Lower Sales, Volumes Amid COVI..
MT
01/05SMITH & NEPHEW : Arthrex's Initial Merits Brief – Making The Case For Pate..
AQ
01/04SMITH & NEPHEW : Completes $240 Million Acquisition of Integra LifeSciences' Ext..
MT
01/04Smith & Nephew Plc Smith+Nephew Completes Orthopaedics Acquisition
DJ
01/04SMITH & NEPHEW : +Nephew completes Extremity Orthopaedics acquisition
PU
01/04SMITH & NEPHEW PLC : Acquisition
CO
More news
Financials (USD)
Sales 2020 4 590 M - -
Net income 2020 377 M - -
Net Debt 2020 1 638 M - -
P/E ratio 2020 52,4x
Yield 2020 1,33%
Capitalization 18 753 M 18 762 M -
EV / Sales 2020 4,44x
EV / Sales 2021 3,75x
Nbr of Employees 17 500
Free-Float 98,7%
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 23,23 $
Last Close Price 21,43 $
Spread / Highest target 25,5%
Spread / Average Target 8,43%
Spread / Lowest Target -15,7%
EPS Revisions
Managers and Directors
NameTitle
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors